HIV Envelope Protein gp41
"HIV Envelope Protein gp41" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING.
| Descriptor ID |
D015700
|
| MeSH Number(s) |
D12.776.543.512.500.330 D12.776.964.775.325.164.200 D12.776.964.775.562.500.200 D12.776.964.970.880.325.164.200 D12.776.964.970.880.910.330 D23.050.327.520.330
|
| Concept/Terms |
HIV Envelope Protein gp41- HIV Envelope Protein gp41
- Envelope Protein gp41, HIV
- HTLV-III gp41
- gp41(HIV)
- HIV Transmembrane Protein gp41
- env Protein gp41, HIV
- gp41 Envelope Protein, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Envelope Protein gp41".
Below are MeSH descriptors whose meaning is more specific than "HIV Envelope Protein gp41".
This graph shows the total number of publications written about "HIV Envelope Protein gp41" by people in this website by year, and whether "HIV Envelope Protein gp41" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Envelope Protein gp41" by people in Profiles.
-
Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein. PLoS One. 2016; 11(7):e0158861.
-
Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor. J Neuroimmune Pharmacol. 2016 09; 11(3):601-10.
-
Efficient delivery of miR-122 to regulate cholesterol metabolism using a non-covalent peptide-based strategy. Mol Med Rep. 2013 Nov; 8(5):1472-8.
-
Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS Pathog. 2011 Sep; 7(9):e1002234.
-
Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. Expert Rev Vaccines. 2010 Jun; 9(6):645-64.
-
Emerging studies of human HIV-specific antibody repertoires. Vaccine. 2010 May 26; 28 Suppl 2:B18-23.
-
Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail. Virology. 2008 Jan 05; 370(1):130-41.
-
Treatment of human immunodeficiency virus (HIV) in children using antiretroviral drugs. Semin Pediatr Infect Dis. 2005 Apr; 16(2):116-24.
-
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis. 2004 Mar 15; 189(6):1075-83.
-
HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity. Mol Immunol. 2004 Feb; 40(13):949-61.